PMPRB finds price of Soliris was/is excessive & orders @AlexionPharma to pay gov & lower price. Learn: @AHUSCanada &

Patented Drug Pricing: The PMPRB Releases New Price-Review Guidelines - Mondaq: Patented Drug Pricing: The PMPRB Releases New Price-Review Guidelines  Mondaq

New PMPRB Draft Guidelines outline administrative process for excessive price hearing recommendations

This is something the Canadian PMPRB does and I'm surprised that it hasn't been simply cut-and-pasted into the FDA's operating methods already, along with all of the other stuff the PMPRB does - one of the few elements of so-called "good government" I've ever seen.

PMPRB releases Annual Public Drug Plan Expenditure Report (2022/23)

New annual report (covering 2023) of Canada's Patented Medicine Prices Review Board #PMPRB is out.
Of note: "The R&D-to-sales ratio was 3.7% in 2023, an increase from 2022". Since 3.7%<10%, it has now been under the industry commitment of 10% for the past 23 years. 💊💰 www.canada.ca/content/dam/...

Buried in an Annex to yesterday's federal budget was a very curious statement about the #PMPRB, Canada's drug pricing regulator.

In order to cut costs by 15% (as almost all federal agencies have been mandated to do), the Board would 'modernise its hearings':

budget.canada.ca/2025/report-...

1/4

Lots of interesting stuff in The Trudeau Record, the book mentioned here c/o @policyalternatives.bsky.social.
(including my chapter, "Calling the Shots: Canada's Big Pharma-first response to COVID-19", covering ground from vaccine equity, TRIPS & the Pandemic Agreement to PMPRB reform & pharmacare).

Or you could just review and respond to price gouging through regulation:

[In Canada]...under the Patent Act.... mandated to protect the interests of ... consumers by ensuring that the prices of patented medicines... are not excessive. ...PMPRB can order price reductions offset of excess revenues.

https://www.ippractice.ca/2022/04/pmprb-9/?utm_campaign=twitter&utm_medium=twitter&utm_source=twitter

Fast forward to 2022 and many twists and turns later, only one part of those reforms remained. (For background, see my letter of resignation from the #PMPRB here: cdn.dal.ca/content/dam/...)

PMPRB releases Annual Public Drug Plan Expenditure Report (2022/23)

Various changes coming at end of June/early July for the Patented Medicines Prices Review Board https://www.ippractice.ca/2021/06/pmprb-6/?utm_campaign=twitter&utm_medium=twitter&utm_source=twitter

I'm Canadian also, when did I accuse you of not being Canadian? What is "PMPRB"? If there is a better way I'm totally open to suggestions as I'm just spitballing.

Innovative Medicines Canada @innovativemeds and 16 of its member companies seeks Judicial Review of PMPRB regulatory changes <a href="http://bit.ly/2kkrox3" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">http://bit.ly/2kkrox3 <a href="http://bit.ly/2k4nCrj" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">http://bit.ly/2k4nCrj

Updated PMPRB Guidelines expected in summer 2025 and NPDUIS releases ninth edition of the Meds Entry Watch Report

“On Nov. 28, 2022, Minister Duclos wrote a letter to the acting chair of the PMPRB, personally making a case for a delay of the reform process.”

https://breachmedia.ca/after-pharma-lobbying-minister-intervened-to-suspend-drug-price-reform/

👀In a further twist, in the announcement the chairperson was resigning & "The Board and #PMPRB staff are grateful for the services of Mr. Digby and wish him success in his future endeavours", it... wasn't clear said future endeavours were running for the Green Party: www.tomdigby.ca/_files/ugd/1...

PMPRB announces Anie Perrault as acting Chairperson and releases latest expenditure report on private drug plan costs and utilization

The only thing is that the PMPRB hasn't had a hearing in quite some time. And if you go to their site, you'll see there are 'no matters' pending before the Board:

www.canada.ca/en/patented-...

2/4

It sounds like a good idea, right?

Unfortunately the cost of standing up a public drug manufacturer is insane. The reputational cost to Canada of cancelling patents would also be terrible.

Besides, Canada's mechanism for controlling patented drug prices is the PMPRB. Leverage them better instead.

A different 'philosophy' steers new drug pricing guidelines, says top PMPRB bureaucrat after contentious path to rule changes www.hilltimes.com/story/2025/0... @tessiesanci.bsky.social @hilltimes.com

𝗠𝗼𝗿𝗲 𝗻𝗲𝘄𝘀 ⇢ CanadaHealthwatch.ca 🍁

PMPRB finds Sandoz Canada a 'patentee' for some pricing reporting obligations <a href="http://bit.ly/Rn3ZSQ" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">http://bit.ly/Rn3ZSQ <a href="http://bit.ly/O0LR25" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">http://bit.ly/O0LR25

Some of the more recent reports, for those who are following along. Feel free to add links:

May 2015: CORD’s National #raredisease Strategy:

June 2016: PMPRB Guidelines Modernization – Discussion Paper:

A different ‘philosophy’ steers new drug pricing guidelines, says top PMPRB bureaucrat after contentious path to rule changes

www.hilltimes.com/story/2025/0...